Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00061932
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00062127
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00062374
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2010-02-12
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00062322
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
- Conditions
- First Posted Date
- 2003-06-05
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 7
- Registration Number
- NCT00008424
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
- Conditions
- Interventions
- First Posted Date
- 2003-05-22
- Last Posted Date
- 2014-02-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 20
- Registration Number
- NCT00006095
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇦🇺Princess Margaret Hospital for Children, Perth, Western Australia, Australia
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
- Conditions
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT00004068
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT00059761
- Locations
- 🇺🇸
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
🇺🇸Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Florida Shands Cancer Center, Gainesville, Florida, United States
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 38
- Registration Number
- NCT00004095
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-05-05
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT00005818
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.